{
    "clinical_study": {
        "@rank": "6565", 
        "acronym": "PaneLux PTCA", 
        "brief_summary": {
            "textblock": "The propose of this study is to demonstrate, whenever using Drug Eluting Stent is not\n      possible, the clinical security at 12 months, of the combinaison Bare Metal Stent plus Drug\n      Eluting Balloon."
        }, 
        "brief_title": "PaneLux PTCA : Proposing an Alternative Treatment to patiEnts for Whom DES Implantation is Not Indicated, Thanks to Pantera LUX Drug Eluting Balloon", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Coronary Artery Disease", 
            "High Bleeding Risk Patients"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Hemorrhage"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subject has provided a written informed consent\n\n          2. Subject >/= 18 years.\n\n          3. Patient affiliated to social security\n\n          4. Patient acceptable candidate who accept to be contacted at different terms of\n             clinical follow up (1, 6 and 12 months)\n\n          5. Subject eligible for percutaneous coronary intervention AND undergoing a chronical\n             oral anticoagulant treatment OR undergoing any semi-urgent invasive or non cardiac\n             surgical planned intervention with major bleeding risks\n\n          6. Subject eligible for Dual Anti Platelet Therapy (DAPT) of acetyl salicylic acid and\n             clopidogrel for at least 3 weeks\n\n          7. De Novo coronary lesions: >/= 50% - <100%\n\n          8. Subject, vessels and target lesion eligible for angioplasty with PRO-Kinetic Energy\n             stent implantation and final post-dilatation with Pantera Lux drug eluting balloon.\n\n          9. Target lesion length </= 26 mm , visual estimation or by Quantitative Coronary\n             Angiography (QCA)\n\n         10. Reference diameters targeted vessels >/=2.5mm and </= 4.0 mm (visual estimation or\n             QCA)\n\n        Exclusion Criteria:\n\n          1. Pregnant or breast feeding females or females who intend to become pregnant during\n             the time of the study\n\n          2. Subject with a life expectancy less than 1 year\n\n          3. Vulnerable subject, protected by law, unable to give his/her consent\n\n          4. Subject currently enrolled in other medical or drug study and has not reached the\n             primary outcome measures of that study\n\n          5. Subject unable to be contacted for the clinical follow up at 1, 6 and 12 months\n\n          6. Subject under chronical oral anti-coagulant treatment (optionnal indication)\n\n          7. Subject undergoing any urgent invasive or surgical intervention with major bleeding\n             risk, which can not maintain dual anti-platelet therapy (DAPT) for at least 3 weeks\n\n          8. In stent restenotic lesion\n\n          9. Target lesion on vessels with nominal diameter < 2.5 mm\n\n         10. Target lesion is located in or supplied by an arterial or venous bypass graft\n\n         11. Chronical Total occlusion (CTO)\n\n         12. Angioplasty indication for STEMI\n\n         13. Patient with signs of cardiogenic shock\n\n         14. Angioplasty antecedent with stent implantation (before 12 months for DES, before 6\n             months for BMS)\n\n         15. \"Staged procedure\" > 8 days after the initial angioplasty\n\n         16. Documented left ventricular ejection fraction (LVEF) </= 30%\n\n         17. Target lesion requiring before stent implantation a device other than a\n             pre-dilatation balloon (including, but not only restricted to laser, cutting balloon,\n             directional coronary atherectomy, rotational atherectomy etc\u2026)\n\n         18. Known allergies to acetylsalicylic acid, active agent such Paclitaxel, Expicients\n             like BHTC (Butiriltri-n-hexyl citrate), CoCr, Silicon Carbide."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01930903", 
            "org_study_id": "201202"
        }, 
        "intervention": {
            "description": "All patients are treated with the PRO-Kinetic Energy Stent and Pantera Lux drug eluting balloon for the last post dilatation.", 
            "intervention_name": "Pantera Lux Drug Eluting Balloon", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "PRO-Kinetic Energy BMS + Pantera Lux DEB combination", 
        "lastchanged_date": "February 6, 2014", 
        "location": {
            "contact": {
                "last_name": "J\u00e9r\u00f4me Roncalli, Prof", 
                "phone": "+33561323334"
            }, 
            "facility": {
                "address": {
                    "city": "Toulouse", 
                    "country": "France"
                }, 
                "name": "Chu Toulouse"
            }, 
            "investigator": {
                "last_name": "J\u00e9r\u00f4me Roncalli, Prof", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "official_title": "Proposing an Alternative Treatment to patiEnts for Whom DES Implantation is Not Indicated, Thanks to Pantera LUX Drug Eluting Balloon", 
        "overall_contact": {
            "email": "marie.gabillet@biotronik.com", 
            "last_name": "Marie Gabillet", 
            "phone": "+33675547025"
        }, 
        "overall_contact_backup": {
            "email": "nicolas.canot@biotronik.com", 
            "last_name": "Nicolas Canot", 
            "phone": "+33146759660"
        }, 
        "overall_official": {
            "affiliation": "CHU Toulouse, H\u00f4pital Rangueil, TSA 50032, 31059 TOULOUSE Cedex 9", 
            "last_name": "J\u00e9r\u00f4me Roncalli, Prof", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "TLF is defined as a composite of cardiac death, any target vessel myocardial infarction (MI), urgent coronary artery bypass graft (CABG) and clinically driven target lesion revascularization (TLR).", 
            "measure": "Target Lesion Failure (TLF) at 12 months.", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01930903"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Target Lesion Failure", 
                "safety_issue": "Yes", 
                "time_frame": "1 and 6 months"
            }, 
            {
                "measure": "Bleeding rate according to BARC definition", 
                "safety_issue": "Yes", 
                "time_frame": "1, 6 and 12 months"
            }, 
            {
                "measure": "Clinically driven target vessel revascularization", 
                "safety_issue": "Yes", 
                "time_frame": "1, 6 and 12 months"
            }, 
            {
                "description": "Cardiac death, stroke, myocardial infarction (Q wave and non Q wave) and TVR by non planned angioplasty or bypass graft", 
                "measure": "MACCE", 
                "safety_issue": "Yes", 
                "time_frame": "1, 6 and 12 months"
            }, 
            {
                "measure": "All deaths", 
                "safety_issue": "Yes", 
                "time_frame": "1, 6 and 12 months"
            }, 
            {
                "measure": "Myocardial Infarction (MI) (Q wave and non Q wave)", 
                "safety_issue": "Yes", 
                "time_frame": "1, 6 and 12 months"
            }, 
            {
                "measure": "Definite incidence of stent thrombosis", 
                "safety_issue": "Yes", 
                "time_frame": "1, 6 and 12 months"
            }, 
            {
                "measure": "Clinically driven target lesion revascularization", 
                "safety_issue": "Yes", 
                "time_frame": "1, 6 and 12 months"
            }, 
            {
                "measure": "Target lesion failure for patients >/= 80 years", 
                "safety_issue": "Yes", 
                "time_frame": "1, 6 and 12 months"
            }, 
            {
                "measure": "Bleeding rate according to BARC definition for patients >/= 80 years", 
                "safety_issue": "Yes", 
                "time_frame": "1, 6 and 12 months"
            }, 
            {
                "measure": "Target lesion failure for kidney failure patients (clearance < 30 ml/ min)", 
                "safety_issue": "Yes", 
                "time_frame": "1, 6 and 12 months"
            }, 
            {
                "measure": "Bleeding Rate according to BARC definition for kidney failure patients (clearance < 30 ml/ min)", 
                "safety_issue": "Yes", 
                "time_frame": "1, 6 and 12 months"
            }
        ], 
        "source": "Biotronik France", 
        "sponsors": {
            "collaborator": {
                "agency": "Biostatistics : Medpass International, 95 bis boulevard Pereire, 75017 Paris", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Biotronik France", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}